Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How a Tumor Grows Can Predict Response to Cancer Therapy

By University of Southern California | December 21, 2017

Individual tumors respond differently to cancer drugs, if at all. Until now, it remained a mystery why tumors have different reactions to the exact same therapy. But a new study at the USC Viterbi School of Engineering finds that tumor growth properties can influence response to cancer drugs.

“Identifying a measurement or quantity that predicts how specific tumors will respond, called a predictive biomarker, is extremely valuable to cancer research,” said Stacey Finley, a USC assistant professor of Biomedical Engineering and co-author to the study. Finley, a Gordon S. Marshall Early Career Chair, is also a faculty member of the new USC Michelson Center for Convergent Bioscience.

Tumors exploit a biological process called angiogenesis, which is the formation of new blood vessels from pre-existing ones. In order to grow and multiply, tumors source nutrients delivered by this new vasculature. But tumor growth will slow down if proteins like vascular endothelial growth factor (VEGF), an angiogenesis promoter, are waylaid.

The research team used a computational model of tumor-bearing mice (verified by published experimental data) to investigate response to VEGF-inhibiting drugs and how this response is affected by tumor development. The model illuminated that certain properties of tumor growth help forecast whether drug therapy will thwart tumor expansion.

“We found that certain parameters about the way the tumor grows could successfully and accurately predict the response to anti-angiogenic treatment that inhibits VEGF signaling in the mouse,” Finley said. “Using the characteristics of the tumor’s growth, we can predict how effective the anti-angiogenic therapy will be, or whether the tumor’s growth will slow down, even before treatment begins.”

A next step in the research includes a mathematical model to simulate a virtual population of mice randomly assigned different tumor growth parameters. The model will mimic tumor growth with and without drug therapy- and be able to predict mice who respond to drug therapy (resulting in slower tumor growth) and mice with no effect. The research team will further use experimental data to validate the model’s predictions.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE